![conference banner](/images/conference-banner.jpeg)
Abstract
Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.
As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.
Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Keywords: Antiplatelets, stroke, prevention.
Current Vascular Pharmacology
Title:Antiplatelets in Stroke Prevention
Volume: 11 Issue: 6
Author(s): Antonio Pinto, Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Butta and Giuseppe Licata
Affiliation:
Keywords: Antiplatelets, stroke, prevention.
Abstract: Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.
As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.
Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Export Options
About this article
Cite this article as:
Pinto Antonio, Raimondo Di Domenico, Tuttolomondo Antonino, Butta Carmelo and Licata Giuseppe, Antiplatelets in Stroke Prevention, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128112915
DOI https://dx.doi.org/10.2174/157016111106140128112915 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine- nitrone Derivatives as Antioxidants
Letters in Drug Design & Discovery PDE-5 Inhibitors: Clinical Points
Current Drug Targets Genetically Engineered Bacteriocins and their Potential as the Next Generation of Antimicrobials
Current Pharmaceutical Design The Evidence for Automated Grading in Diabetic Retinopathy Screening
Current Diabetes Reviews Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry The Use of n-3 Polyunsaturated Fatty Acids as Therapeutic Agents for Inflammatory Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research What’s Age Got to do with it? A Review of Contemporary Revascularization in the Elderly
Current Cardiology Reviews From the Editors Perspective: Aquaporins to Apoptosis
Current Neurovascular Research Promising Use of the New Biologics in the Management of Drug-Induced Hypersensitivity Reactions: Preliminary Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases
Current Stem Cell Research & Therapy Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews The Recent Advances in the Function and Mechanism of Caveolin-1 in Retinal Neovascularization
Current Drug Targets Pulmonary Hypertension and Lung Transplant in Connective Tissue Disease-Interstitial Lung Disease
Current Respiratory Medicine Reviews